Kombinasyon ilaç uygulamalarının over kanseri kemodirenci üzerindeki etkileri

Ovarian cancer is one of the deadliest gynecological cancers with high mortality rate and the 5-year survival rate is less than 50 %. Besides the lack of early diagnostic methods and the lack of characteristic disease symptoms, enhanced chemotherapy resistance and relapse are responsible for the high mortality rate of ovarian cancer patients. Therefore, novel therapeutic strategies for overcoming chemoresistance in ovarian cancer are urgently needed. Here, we used a combination of chemotherapeutic agents (bortezomib, olaparib and cisplatin) to overcome ovarian cancer chemoresistance. In particular drug concentrations tested, we observed that combination treatment of bortezomib and olaparib enhances cytotoxicity when compared to drugs alone. We further elucidate a potential mechanism that how combination treatment regulates expression of DYNLL1 which functions in several cellular processes including apoptosis, DNA damage response and chemoresistance. These results indicate that combination treatments have potential benefits to decrease ovarian cancer chemoresistance in vitro, possibly by regulating DYNLL1 expression in part.